ライフサイエンスコーパス: alkaline phosphatase

1 vity using a phage-based enzymatic reporter, alkaline phosphatase.

2 Ts were degraded by an intracellular enzyme, alkaline phosphatase.

3 lpha-naphthol by anti-fluorescein-conjugated alkaline phosphatase.

4 idues in the active site of Escherichia coli alkaline phosphatase.

5 kers runt-related transcription factor 2 and alkaline phosphatase.

6 o the diseases and also plasma bilirubin and alkaline phosphatase.

7 , hemoglobin, prostate-specific antigen, and alkaline phosphatase.

8 nsferase, gamma-glutamyl transpeptidase, and alkaline phosphatase.

9 1C, cholesterol, hemoglobin, creatinine, and alkaline phosphatase.

10 ic activity, procollagen I, osteocalcin, and alkaline phosphatase.

11 ough the bead-based binding assay with EphB4-alkaline phosphatase.

12 ibrils and increased expression of Runx2 and alkaline phosphatase.

13 pe was associated with reduced expression of alkaline phosphatase.

14 atients, 9%; all grade 3), raised amounts of alkaline phosphatase (11 patients, 9%]), and anaemia (ni

15 r mean +/- SE markers of bone turnover (bone alkaline phosphatase: 15.8 +/- 0.59 compared with 14.0 +

16 gamma-glutamyl transferase (360.53 U/L), and alkaline phosphatase (197.06 U/L).

17 measurements of serum PTH, calcium and bone alkaline phosphatase, 24-h urine calcium and bone densit

18 evels were alanine aminotransferase 892 U/L, alkaline phosphatase 358 U/L, and total bilirubin 6.1 mg

19 ransferase, 21.77 U/L (18.96-24.59 U/L); for alkaline phosphatase, 88.35 U/L (58.94-117.76 U/L); and

20 uperparamagnetic beads were derivatized with alkaline phosphatase (a common enzyme label for biochemi

21 colonic pathology associated with intestinal alkaline phosphatase, a mucosal defense factor that deto

22 2 expression, some dividing cells, and clear alkaline phosphatase activity (early bone marker).

23 This was confirmed by alkaline phosphatase activity and Alizarin red and Von K

24 f terminal differentiation such as increased alkaline phosphatase activity and an elevated level of m

25 r time, resulting in significantly increased alkaline phosphatase activity and calcium deposition of

26 The osteoblastic functions of alkaline phosphatase activity and calcium mineralization

27 at results from increased tissue-nonspecific alkaline phosphatase activity and diminished ATP availab

28 function were decreased, as evidenced by low alkaline phosphatase activity and matrix mineralization.

29 Wnt10b protein levels and induced increased alkaline phosphatase activity and mineralization in oste

30 om the Sirt1(DeltaOsx1) mice exhibited lower alkaline phosphatase activity and mineralization, as wel

31 n, the number of committed osteoprogenitors, alkaline phosphatase activity and mineralization.

32 enrichment in polyP coincided with enhanced alkaline phosphatase activity and substitution of sulfol

33 quantitative estimates for the intracellular alkaline phosphatase activity at five different temperat

34 reduced femur length, and 30% elevated serum alkaline phosphatase activity compared to wild type.

35 Alkaline phosphatase activity did not increase in respon

36 ipocytes, promoted DP markers and functional alkaline phosphatase activity from the DP cells.

37 s and spent hops induced estrogen responsive alkaline phosphatase activity in endometrial cancer cell

38 riments, prelamin A-expressing VSMCs induced alkaline phosphatase activity in mesenchymal progenitor

39 or addition of OC protein partially rescued alkaline phosphatase activity in periodontal ligament (P

40 A significant increase in alkaline phosphatase activity was also seen on FA-coated

41 s also increased under these conditions, but alkaline phosphatase activity was not significantly alte

42 BMP-2-induced Smad 1/5/8 phosphorylation and alkaline phosphatase activity were both enhanced by the

43 of osteogenic related markers (osteopontin, alkaline phosphatase activity, Alizarin red, and Von Kos

44 significant effects on protein synthesis or alkaline phosphatase activity, and drove discrete change

45 Cooling disrupted sebocyte cell membranes, alkaline phosphatase activity, and significantly reduced

46 Moreover, alkaline phosphatase activity, calcium deposition and ac

47 tment can greatly promote MSC proliferation, alkaline phosphatase activity, calcium deposition and to

48 ontext, among all the compounds screened for alkaline phosphatase activity, four compounds 10, 14, 18

49 olangiocytes, including bile acids transfer, alkaline phosphatase activity, gamma-glutamyl-transpepti

50 or is based on the inhibition of immobilized alkaline phosphatase activity, in the presence of the ph

51 potential confounders, such as inflammation, alkaline phosphatase activity, low serum albumin, renal

52 ibited enhanced differentiation indicated by alkaline phosphatase activity, mineral deposition, and t

53 st differentiation as indicated by increased alkaline phosphatase activity, mineralization, and up-re

54 n factor-15 (P = 0.0001), and calcification (alkaline phosphatase activity, P < 0.01; osteocalcin, P

55 mal body weight, long bone length, and serum alkaline phosphatase activity, suggesting that tooth dys

56 inhibited osteoblast differentiation marker alkaline phosphatase activity, while miR-138 inhibitor a

57 of nuclear factor-kappaB ligand (RANKL), and alkaline phosphatase activity.

58 kly but had deficient mineral apposition and alkaline phosphatase activity.

59 n, and reduced type 1 collagen secretion and alkaline phosphatase activity.

60 acental alkaline phosphatase has an enhanced alkaline phosphatase activity.

61 d the majority of them stained intensely for alkaline phosphatase activity.

62 8 inhibitor and OC protein addition enhanced alkaline phosphatase activity.

63 protective effect associated with intestinal alkaline phosphatase activity.

64 as well as the bilirubin, transaminases, and alkaline phosphatase, after 12 months of UDCA.

65 consumption was associated with lower serum alkaline phosphatase; alanine aminotransferase; aspartat

66 fections (HR 1.52-1.67, P = 0.007-0.03), and alkaline phosphatase (ALP) (HR 1.05, P < 0.001).

67 biliary cirrhosis (95% women) and levels of alkaline phosphatase (ALP) 1.5- to 10-fold the upper lim

68 Cs entrapped in ECM gels exhibited increased alkaline phosphatase (ALP) activity and expression of os

69 ; this was verified by observations of lower alkaline phosphatase (ALP) activity and higher expressio

70 ibes the use of BODIPY analogs for detecting alkaline phosphatase (ALP) activity and inhibition.

71 , and 2.5% to 10% of PRP gradually increased alkaline phosphatase (ALP) activity in the cells in a do

72 new colorimetric assay for the detection of alkaline phosphatase (ALP) activity is reported based on

73 n this study, the differentiation of DFCs by alkaline phosphatase (ALP) activity measurement, alizari

74 nic differentiation was analyzed in terms of alkaline phosphatase (ALP) activity of KS483-4C3 mouse p

75 ession of osteogenic related genes, elevated alkaline phosphatase (ALP) activity, and enhanced minera

76 tiation potential, as evidenced by increased alkaline phosphatase (ALP) activity, compared to the dir

77 platform for biokits and biosensors based on alkaline phosphatase (ALP) activity/inhibition in the pr

78 iation and mineralization as demonstrated by alkaline phosphatase (ALP) activity/staining as well as

79 ver enzymes, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase

80 ase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamytransferase

81 Protein kinase (PKA) and alkaline phosphatase (ALP) are clinically relevant enzym

82 the Wnt signaling antagonist Sclerostin, and alkaline phosphatase (ALP) are two additional targets of

83 drolysis of 4-nitrophenylphosphate (pNPP) by alkaline phosphatase (ALP) bound on paramagnetic-beads w

84 Alkaline phosphatase (ALP) catalyzes the hydrolisis of s

85 e ALPL gene, encoding the tissue-nonspecific alkaline phosphatase (ALP) enzyme.

86 The self-assembly can be triggered by alkaline phosphatase (ALP) in solution or in situ by the

87 Alkaline phosphatase (ALP) was visualized in the vossicl

88 Subsequent testing showed elevated serum alkaline phosphatase (ALP), a GPI-anchored enzyme, in al

89 racteristics to be identified, the levels of alkaline phosphatase (ALP), a marker commonly used in cl

90 ALPL encodes tissue nonspecific alkaline phosphatase (ALP), an enzyme that promotes mine

91 ase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transamin

92 mined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation o

93 rase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidas

94 Expression of alkaline phosphatase (ALP), in vitro mineralization alon

95 e substrate 1-naphthyl phosphate (1-NP), for alkaline phosphatase (ALP).

96 endpoints for measuring disease progression: alkaline phosphatase (ALP); transient elastography (TE);

97 patic autoimmune disorders 46%; normal serum alkaline phosphatases (ALP) 74%; ALP above 1.5 times the

98 ponse to ursodeoxycholic acid therapy (i.e., alkaline phosphatase [ALP] >1.67x upper limit of normal

99 [AST], gamma-glutamyl transpeptidase [GGT], alkaline phosphatase [ALP], twice weekly; n = 3,216) wer

100 viously showed that the zebrafish intestinal alkaline phosphatase (ALPI) gene alpi.1 was induced by G

101 ity of the differentiation marker intestinal alkaline phosphatase (ALPi).

102 T63 increased the alkaline phosphatase (ALPL) activity and mineralization

103 DHT treatment increased tissue non-specific alkaline phosphatase (Alpl) mRNA expression.

104 ion, and up-regulation of bone marker genes (alkaline phosphatase/ALPL, osteopontin/SPP1, and bone si

105 Previously, we showed that the placental alkaline phosphatase (ALPP) mRNA can be localized to the

106 tively killing cancer cells that overexpress alkaline phosphatases (ALPs).

107 strates of both carboxylesterases (CESs) and alkaline phosphatases (ALPs).

108 ALPL encodes tissue-nonspecific alkaline phosphatase, an enzyme expressed in bone, teeth

109 However, for alkaline phosphatase, an SP that is recognized for post-

110 nalyzed the progression of mineralization by alkaline phosphatase and alizarin red staining.

111 Use of ursodeoxycholic acid can improve alkaline phosphatase and bilirubin concentrations but do

112 Alkaline phosphatase and bilirubin levels correlate with

113 y bioconverted into parent drug 1 in vivo by alkaline phosphatase and esterase in a stepwise manner,

114 he first report where two different enzymes (alkaline phosphatase and horseradish peroxidase) were us

115 t at P <0.001) upregulated the expression of alkaline phosphatase and in vitro mineralized nodule for

116 strong antifolding activity, in complex with alkaline phosphatase and maltose-binding protein capture

117 of sphingosine-1-phosphate (S1P), increased alkaline phosphatase and mineralized nodules in osteobla

118 xpression and activity of tissue-nonspecific alkaline phosphatase and mitochondrial dysfunction, whic

119 Serum bone-specific alkaline phosphatase and osteocalcin decreased on parica

120 creases in OA and the bone-formation markers alkaline phosphatase and osteocalcin in D2J mice.

121 BMP-2 autoregulation and the expressions of alkaline phosphatase and osterix that are necessary for

122 Serum total alkaline phosphatase and plasma cross-linked C-terminal

123 erentiation and, consequently, expression of alkaline phosphatase and PPi breakdown, further contribu

124 cell characteristics, staining positive for alkaline phosphatase and SSEA4, in addition to expressin

125 Elevated alkaline phosphatase and the presence of visceral metast

126 gitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that dif

127 Diffuse MPD dilation, serum CA19-9, serum alkaline phosphatase, and absence of extrapancreatic cys

128 y and mineralization such as Col10, osterix, alkaline phosphatase, and bone sialoprotein.

129 keleton, Ki67, expression of osteopontin and alkaline phosphatase, and formation of mineralized nodul

130 minotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase leve

131 ic steatosis, elevated aminotransferases and alkaline phosphatase, and hypercholesterolemia, as well

132 ignificant laboratory variables (hemoglobin, alkaline phosphatase, and international normalized ratio

133 ic differentiation markers: type I collagen, alkaline phosphatase, and osteocalcin.

134 es (1, 4-beta-cellobiosidase, arylsulfatase, alkaline phosphatase, and phenol oxidase) suggesting sal

135 onent of the phosphate transporter, phoA, an alkaline phosphatase, and porin PMM0709, were strongly u

136 frican-American race, higher serum levels of alkaline phosphatase, and prior heart disease or maligna

137 e PSA, bone pain, liver disease, hemoglobin, alkaline phosphatase, and subsequent PSA and RECIST resp

138 acterial proteins, including phospholipases, alkaline phosphatase, and the CFTR inhibitory factor (Ci

139 f genes, such as matrix metalloproteinase-2, alkaline phosphatase, and transforming growth factor bet

140 kers relative to bone turnover markers, bone alkaline phosphatase, and urinary N-terminal cross-linke

141 USF1 activation, osteochondrogenic programs, alkaline phosphatase, and vascular smooth muscle lineage

142 of dissolved inorganic phosphorus (DIP), and alkaline phosphatase (AP) has been the major research fo

143 Several lines of evidence show that serum alkaline phosphatase (AP) is not only a signpost of chol

144 ate that soluble 5'-nucleotidase (5'-NT) and alkaline phosphatase (AP) mediate conversion of AMP to a

145 a superfamily, we turned to the well-studied alkaline phosphatase (AP) superfamily, comparing three o

146 phate monoester (pNPP(2-)) in enzymes of the alkaline phosphatase (AP) superfamily, R166S AP and wild

147 osphate monoesterases and diesterases of the alkaline phosphatase (AP) superfamily.

148 e we have studied the catalytic mechanism of alkaline phosphatase (AP), which is one of the most cata

149 accessed by microbes employing a variety of alkaline phosphatase (APase) enzymes.

150 rent concentrations of antibody labeled with alkaline phosphatase are immobilized on the pin-heads an

151 Alkaline phosphatases are ubiquitous extracellular enzym

152 clamp studies, treatment of the channel with alkaline phosphatase as well as analysis of dephosphomim

153 sion of bone-specific genes, osteocalcin and alkaline phosphatase as well as through the detection of

154 cantly (P < 0.05) enhanced the expression of alkaline phosphatase, as well as the rate and volume of

155 t and showed elevation of serum liver tests (alkaline phosphatase, aspartate aminotransferase, alanin

156 Serum biochemistries, including alkaline phosphatase, aspartate aminotransferase, and bi

157 educed serum alanine aminotransferase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and d

158 Levels of serum bone alkaline phosphatase (B-ALP) and myeloperoxidase (MPO) a

159 interleukin (IL)-1beta and IL-10, serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid

160 to bone turnover, calcium, phosphorus, bone alkaline phosphatase (b-ALP), and terminal C telopeptide

161 ta, osteoprotegerin (OPG), and bone-specific alkaline phosphatase (BALP) serum levels were determined

162 liver and kidney enzymes, and bone-specific alkaline phosphatase (BALP) serum levels were evaluated.

163 les were collected to evaluate bone-specific alkaline phosphatase (BALP), leukogram, and dosages of a

164 runt-related transcriptor factor 2 (RUNX2), alkaline phosphatase, CD105, and CD166 during osteogenic

165 colony-forming units (CFU), CFU-positive for alkaline phosphatase (CFU-AP(+)), and mineralizing nodul

166 easured reaction kinetics of calf intestinal alkaline phosphatase (CIAP) immobilized in benzophenone-

167 % CI 16 months-NA) than for patients with an alkaline phosphatase concentration equal to or greater t

168 vival was longer for: patients with baseline alkaline phosphatase concentration less than the upper l

169 operative Oncology Group performance status, alkaline phosphatase concentration, haemoglobin concentr

170 The powerful enzyme alkaline phosphatase conjugated to the highly specific b

171 The ISH protocol uses alkaline phosphatase-conjugated digoxigenin antibodies f

172 h stripping analysis of enzymatically (using alkaline phosphatase) deposited silver.

173 te includes a putative Lon-like protease, an alkaline phosphatase domain protein, a putative RNA-bind

174 ride content and elevated ALT, bilirubin and alkaline phosphatase due to three hepatic defects: 1.6-f

175 essed with age, highly elevated bone-derived alkaline phosphatase, elevated aminotransferases, and el

176 edication and had at least one post-baseline alkaline phosphatase evaluation).

177 istomorphometry, in vitro proliferation, and alkaline phosphatase expression in osteoblasts isolated

178 cimen, employing a well-characterized enzyme alkaline phosphatase for accurate quantification of all

179 Plasma alkaline phosphatase for both cKO models at 24 wk was re

180 xed with the secreted Gaussia luciferase and alkaline phosphatase for simultaneous monitoring of thre

181 Alkaline phosphatase fusion and shaving experiments sugg

182 ng exon of the ancestral tissue-non-specific alkaline phosphatase gene (ALPL).

183 In this study, we map ESEs in the placental alkaline phosphatase gene (ALPP), absent in the correspo

184 ing Brn3a and Brn3b mutant mice in which the alkaline phosphatase gene was knocked-in, we studied the

185 New albumin, bilirubin, and alkaline phosphatase grade 3/4 toxicities were, respecti

186 f KIT D816V EAB >/=25%, tryptase >/=50%, and alkaline phosphatase >/=50% were significantly associate

187 unctional analysis, that the 89Leu placental alkaline phosphatase has an enhanced alkaline phosphatas

188 l intestinal brush-border enzyme, intestinal alkaline phosphatase (IAP), in preventing a high-fat-die

189 tinal production and secretion of intestinal alkaline phosphatase (IAP), which induces changes in the

190 molecular aging and clearance of intestinal alkaline phosphatase (IAP).

191 otein-cholesterol (LDL-C), triglycerides and alkaline phosphatase in 3 independent populations (n > 8

192 ineralized differentiation, osteopontin, and alkaline phosphatase in DPSCs cultured on dentine.

193 nd amplification of the signal by the enzyme alkaline phosphatase in ELISA together with the sensitiv

194 strong fluorescence to both receptors and to alkaline phosphatase in the airway epithelium.

195 ation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%), and aspartate aminotransf

196 s were fatigue (eight [2%] of 370 patients), alkaline phosphatase increase (five [1%]), colitis, and

197 treated cells showed increased expression of alkaline phosphatase, increased matrix, and mineralized

198 e substrate, with and without levamisole, an alkaline phosphatase inhibitor.

199 ty was not affected, however in contrast, an alkaline phosphatase isolated from E. coli was strongly

200 RIgG by using a competitive assay and using alkaline phosphatase-labeled antibody.

201 boratory work-up was remarkable for elevated alkaline phosphatase level (277 U/L [4.6 mkat/L]).

202 eases than those in the placebo group in the alkaline phosphatase level (least-squares mean, -113 and

203 e dehydrogenase level (r = 0.534, P < .001), alkaline phosphatase level (r = 0.572, P < .001), circul

204 rgest diameter of the largest metastasis and alkaline phosphatase level at the time of diagnosis of m

205 An alkaline phosphatase level of > 133 mg/dL (area under th

206 nge, 10-50 U/L [0.17-0.83 mukat/L]), a serum alkaline phosphatase level of 157 U/L (2.62 mukat/L) (no

207 L (reference range, [158-424] x 10(9)/L), an alkaline phosphatase level of 85 U/L (1.42 mukat/L) (nor

208 Blood chemistry tests revealed an alkaline phosphatase level of 93 U/L (1.6 mukat/L) (30-1

209 The primary end point was an alkaline phosphatase level of less than 1.67 times the u

210 elevated aminotransferases, and an elevated alkaline phosphatase level were all significantly more p

211 ver inflammation were a lower BMI and higher alkaline phosphatase level while a factor associated wit

212 ed by previous docetaxel use, baseline total alkaline phosphatase level, and current bisphosphonate u

213 Asian or African American race, an elevated alkaline phosphatase level, and female sex as independen

214 rican American, female, and have an elevated alkaline phosphatase level.

215 us, hypertension, weight loss more than 10%, alkaline phosphatase levels 120 units/L or more, and alb

216 ated serum CA19-9 levels, and elevated serum alkaline phosphatase levels as significant.

217 nd 10 compared to machined Ti; and 2) higher alkaline phosphatase levels at day 10 compared to day 7.

218 aminotransferase, total bilirubin, and serum alkaline phosphatase levels by 86%, 93%, and 55%, respec

219 patients who did and did not develop ALF had alkaline phosphatase levels greater than 2 x ULN.

220 INTERPRETATION: Seladelpar normalised alkaline phosphatase levels in patients who completed 12

221 ansferase, gammaglutamyl transpeptidase, and alkaline phosphatase levels were independent predictors

222 diffuse MPD dilation, serum CA19-9 and serum alkaline phosphatase levels, and absence of extra pancre

223 , phosphate, fibroblast growth factor-23, or alkaline phosphatase levels.

224 ansferase, gammaglutamyl transpeptidase, and alkaline phosphatase levels.

225 ease HSO4(-) by an E2 mechanism, rather than alkaline phosphatase-like S(N)2 substitution by water.

226 e lactone quorum sensing signals, as well as alkaline phosphatase, lipase and chitinase activities.

227 Alkaline phosphatase liver/bone/kidney (ALPL) expression

228 In logistic regression, only higher baseline alkaline phosphatase, lower platelets, and greater hepat

229 low from the significantly lower activity of alkaline phosphatase measured in MCF7 cells and their su

230 P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase more than 101 U/L (HR = 2.8; P = .0

231 onally, PgPE treatment caused an increase in alkaline phosphatase mRNA expression in PDL-CD105(+) cel

232 ach of these approaches stained positive for alkaline phosphatase, NANOG, and Tra-1-60, indicating th

233 of 102 patients), increased concentration of alkaline phosphatase (nine [4%] vs two [2%]), fatigue (s

234 tment, based on a central laboratory ULN for alkaline phosphatase of 116 U/L.

235 posttransplant with ascites, AST 503 IU/mL, alkaline phosphatase of 298 IU/mL, HCV RNA of 12 000 000

236 rioration in liver biochemistry (increase of alkaline phosphatase of 75.6%; P<0.0001; gamma-glutamyl

237 o-controlled, phase 2 trial of patients with alkaline phosphatase of at least 1.67 times the upper li

238 ritin (OR, 1.006; CI, 1.003-1.010; P<0.001), alkaline phosphatase (OR, 1.020; CI, 1.001-1.039; P=0.03

239 The expressions of alkaline phosphatase, osteocalcin, osteonectin, and oste

240 lly significant (P <0.001) downregulation of alkaline phosphatase, osteocalcin, osteonectin/osteopont

241 e was the percentage change from baseline in alkaline phosphatase over 12 weeks, analysed in the modi

242 Blood fluoride (P < .001), alkaline phosphatase (P = .020), daily voriconazole dose

243 Changes by SUVmaxavg correlated with bone alkaline phosphatase (P = 0.0014) but not prostate-speci

244 differed, with significantly lower placental alkaline phosphatase (P<0.05) and Eng (P<0.05) expressio

245 ced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the num

246 tor (TF) chaperone molecules in complex with alkaline phosphatase (PhoA) captured in the unfolded sta

247 Alkaline phosphatase (phosphorus-cycling) activity was n

248 structure of the widely occurring microbial alkaline phosphatase PhoX.

249 Alkaline phosphatases play a crucial role in phosphate a

250 ber of multinucleated and tartrate-resistant alkaline phosphatase-positive cells and Calcr mRNA expre

251 s showed there was a significant increase in alkaline phosphatase-positive colony number at 1 week in

252 GS21680 and dipyridamole treatment increased alkaline phosphatase-positive osteoblasts and diminished

253 Measurements of secreted alkaline phosphatase protein and metabolic activity show

254 The crystal structure of tungstate-bound alkaline phosphatase provides evidence for a covalent ad

255 ty was amplified using rabbit anti-mouse IgG-alkaline phosphatase (RalphaMIgG-ALP) functionalized wit

256 were measured by Griess method and secretory alkaline phosphatase reporter activity assay, respective

257 nse element upstream of a secreted placental alkaline phosphatase reporter gene and accumulation of (

258 ig and anti-FITC conjugated to peroxidase or alkaline phosphatase, respectively.

259 lytic mechanisms underlying Escherichia coli alkaline phosphatase's (AP) remarkable rate enhancement

260 The osteogenic markers, alkaline phosphatase, secreted phosphoprotein 1 (osteopo

261 acterized members of the PHO regulon such as alkaline phosphatases, several proteins, previously not

262 Alkaline phosphatase shifted the Fpassive-sarcomere leng

263 ed OPN and DMP1 associated with an increased alkaline phosphatase staining in the XLH cultures.

264 Periodic Acid Schiff and alkaline phosphatase staining revealed subapical accumul

265 gulating pluripotency by mRNA expression and alkaline phosphatase staining using independent short ha

266 n be used to robustly detect 526 ymol of the alkaline phosphatase streptavidin probe and accurately q

267 Cardiomyocytes were incubated with alkaline phosphatase, subsequently reassessed after a pe

268 fluorescein diphosphate (FDP), a fluorogenic alkaline phosphatase substrate, with and without levamis

269 c domain to be a zinc metalloprotein with an alkaline phosphatase/sulphatase fold containing three di

270 In this context, the members of the alkaline phosphatase superfamily have been extensively s

271 asma levels of gamma-glutamyltransferase and alkaline phosphatase than was early parenteral nutrition

272 mplification step of the enzyme, usually the alkaline phosphatase, that catalyzes the hydrolysis of a

273 sphatidylcholine increased the expression of alkaline phosphatase, the ectonucleotide pyrophosphatase

274 clease I-like 3 (DNASE1L3); IL-1beta (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL);

275 the calcification protein tissue nonspecific alkaline phosphatase (TNAP) into extracellular vesicles,

276 Fgf23 is a suppressor of tissue nonspecific alkaline phosphatase (Tnap) transcription via FGF recept

277 ons of Pi and PPi include tissue-nonspecific alkaline phosphatase (TNAP), progressive ankylosis prote

278 also reduced, paralleling a 78% reduction in alkaline phosphatase (TNAP)-positive adventitial myofibr

279 Here, we found that tissue-nonspecific alkaline phosphatase (TNAP, encoded by the Alpl gene) is

280 luding albumin, fetuin-A, apolipoprotein-A1, alkaline phosphatase, TNFR1 and CD63.

281 ALPL encodes the tissue nonspecific alkaline phosphatase (TNSALP), which removes phosphate g

282 -5-phosphate (PA5P) is cleaved by the enzyme alkaline phosphatase to yield the basic and hydrophilic

283 transferase, alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, albumin, creatini

284 oups were globally reduced using nonspecific alkaline phosphatase, Triton X-100-solubilized membranes

285 der N limitation and a large upregulation of alkaline phosphatase under P limitation.

286 (age, serum prostate-specific antigen level, alkaline phosphatase, use of pain medication, prior chem

287 Here, we explore TS structure in the enzyme alkaline phosphatase using hybrid Quantum Mechanics/Mole

288 D-xylosidase, and phenol oxidase) as well as alkaline phosphatase, using a per unit OM basis.

289 received seladelpar for 12 weeks had normal alkaline phosphatase values at the end of treatment, bas

290 Streptavidin-alkaline phosphatase was then conjugated to the MMC surf

291 candidate gene, ALPP, encoding the placental alkaline phosphatase, was identified as being potentiall

292 ctural and electrostatic features of several alkaline phosphatases, we suggest that this phenomenon i

293 Mean changes from baseline in alkaline phosphatase were -2% (SD 16) in the placebo gro

294 ring skin morphogenesis (NCAM, versican, and alkaline phosphatase) were all severely altered in Tfam(

295 d to evaluate the activity and inhibition of alkaline phosphatase, which can convert adenosine monoph

296 i-inflammatory and antiapoptotic activities; alkaline phosphatase, which detoxifies proinflammatory s

297 her stimulation was inhibited by addition of alkaline phosphatase, which in turn, was reversed by the

298 ver, a significant increase in bone-specific alkaline phosphatase, which is a bone-formation marker,

299 or AST, whichever produced the highest xULN/ alkaline phosphatase x ULN value) of 5 or greater.

300 r than 3 x ULN, a ratio (R) value (ALT x ULN/alkaline phosphatase x ULN) of 5 or greater, or a new ra